News

15 Sep 2017

Visit REPROCELL Stand H2 at ELRIG Drug Discovery 2017 Conference, 3-4 October 2017

Visit REPROCELL Stand H2 at ELRIG Drug Discovery 2017 Conference, 3-4 October 2017
Read More >>

15 Sep 2017

Visit REPROCELL Booth 107 at the SPS Annual Meeting, Berlin, 24-27 September 2017

Visit REPROCELL Booth 107 at the SPS Annual Meeting, Berlin, 24-27 September 2017
Read More >>

06 Sep 2017

Visit REPROCELL Booth A66 at Basel Life Science Week (MipTec), 11-13 September 2017

Basel Life Science Week this year will be held at Basel Congress Centre, Switzerland on 11-13 September 2017. REPROCELL will be at booth A66 at the MipTec Vendor Exhibition, located in Hall 4.1.
Read More >>

10 Aug 2017

PRESS RELEASE: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow

REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK.
Read More >>

1 2 3 4 >>

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

13/05/2016

Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.

Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in chronic kidney disease (CKD). The ex vivo study demonstrated that  vonapanitase removed elastic fibres from human cephalic veins in a dose-dependent manner, as assessed by both desmosine and histological staining of elastic fibres.
 
The study, titled Recombinant Human Elastase Treatment of Cephalic Veins, was published in Cardiovascular Pharmacology: Open Access. Proteons Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors. The full paper can be accessed here

Live chat by BoldChat